Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

NCT02267603 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

NIH

Sponsor class

Conditions

Recurrent Merkel Cell Carcinoma
Stage III Merkel Cell Carcinoma AJCC v7
Stage IIIA Merkel Cell Carcinoma AJCC v7
Stage IIIB Merkel Cell Carcinoma AJCC v7
Stage IV Merkel Cell Carcinoma AJCC v7

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab

Sponsor

National Cancer Institute (NCI)